Alex F Herrera
Overview
Explore the profile of Alex F Herrera including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
133
Citations
3501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thiruvengadam S, Mei M, Chen L, Puverel S, Chen R, Popplewell L, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jul;
24(10):724-731.e1.
PMID: 39043499
Introduction: BV is an antibody-drug conjugate directed against CD30 and is safe and effective in relapsed/refractory (R/R) Hodgkin lymphoma (HL). Most patients with r/r cHL respond well to BV monotherapy;...
12.
Othman T, Frankel P, Allen P, Popplewell L, Shouse G, Siddiqi T, et al.
Haematologica
. 2024 Jul;
110(1):142-152.
PMID: 39021209
Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) transformed from indolent B-cell lymphomas, including Richter transformation, have a poor prognosis. PD-1/PD-L1 antibodies produce modest objective and complete response rates in...
13.
Zain J, Tsai N, Palmer J, Simpson J, Adhikarla V, Bading J, et al.
Blood Adv
. 2024 Jun;
8(18):4812-4822.
PMID: 38838232
Peripheral T-cell lymphomas (PTCLs) have a poor prognosis with current treatments. High-dose chemotherapy followed by autologous hematopoietic cell transplant (AHCT) is used as a consolidation strategy after achieving clinical remission...
14.
Othman T, Baird J, Pak S, Mei M, Herrera A, Mansour J, et al.
Br J Haematol
. 2024 May;
205(1):368-372.
PMID: 38797530
No abstract available.
15.
Epperla N, Hashmi H, Ahn K, Allbee-Johnson M, Chen A, Wirk B, et al.
Br J Haematol
. 2024 May;
205(3):1202-1207.
PMID: 38797526
No abstract available.
16.
Wang T, Ahn K, Shadman M, Kaur M, Ahmed N, Bacher U, et al.
Leukemia
. 2024 May;
38(7):1564-1569.
PMID: 38750138
CD19 CAR T-cell (CAR-T) therapy is commonly administered to patients with relapsed or refractory large B-cell lymphomas (LBCL), but salvage or bridging therapy can sometimes lead to a complete response...
17.
Yi S, Yan Y, Jin M, Bhattacharya S, Wang Y, Wu Y, et al.
J Clin Invest
. 2024 May;
134(10).
PMID: 38747295
No abstract available.
18.
Burton C, Allen P, Herrera A
Am Soc Clin Oncol Educ Book
. 2024 May;
44(3):e433502.
PMID: 38728605
Combination chemotherapy with or without radiation has served as the primary therapeutic option for classic Hodgkin lymphoma (cHL), leading to durable remission in a majority of patients with early- and...
19.
Lurain K, El Zarif T, Ramaswami R, Nassar A, Adib E, Abdel-Wahab N, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):523-530.
PMID: 38714474
Background: Despite a higher risk of classical Hodgkin lymphoma (cHL) in people with HIV and the demonstrated safety and efficacy of PD-1 blockade in cHL, there are limited data on...
20.
Mei M, Tsai N, Palmer J, Armenian S, Chen R, Rosen S, et al.
Clin Lymphoma Myeloma Leuk
. 2024 May;
24(8):537-542.
PMID: 38693037
Introduction: Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in relapsed/refractory (r/r) Hodgkin lymphoma (HL). Although most...